Participation in the study lasts approximately six years (and may be shorter or longer for certain participants). This includes:
a screening period of approximately 35 days,
an initial 24-week treatment period (which may be extended if certain criteria are met and if you continue to benefit from the treatment), and
a follow-up period where you will be contacted approximately every 12 weeks to ask how you are doing (follow up on progress).
The study drug being used in the COMMANDS Trial is is a protein that aims to help increase the production of red blood cells in bone marrow. The study drug will be administered as an injection every three weeks during the treatment period.